SCHEMBL4038206

SCHEMBL4038206

COc1cccc(C(C(=O)NC2CCCCC2)C2(c3ccc(Cl)cc3)Nc3ccccc3N2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
ALDH1A1 P00352 2/20 0.41
NFKB1 P19838 1/20 0.41
CASP3 P42574 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038946 0.86 OPRL1 (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4036130 0.86 NR1H4 (0.42) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL4044209 0.86 HRH3 (0.43) NPC1RAB9ASMN1; SMN2CYP2C19NR1H4
SCHEMBL4040060 0.84 LMNA (0.48) NPC1RAB9AALDH1A1LMNATSHR
SCHEMBL4038094 0.83 TSHR (0.45) SMN1; SMN2CYP1A2CYP2C19ALDH1A1TP53
SCHEMBL4038040 0.81 TSHR (0.38) SMN1; SMN2ALDH1A1MEN1KMT2ATSHR
SCHEMBL4045000 0.80 NR1H4 (0.48) NPC1RAB9ASMN1; SMN2CYP3A4CYP2C19
SCHEMBL4038480 0.80 NR1H4 (0.48) NPC1RAB9ASMN1; SMN2CYP3A4CYP2C19
SCHEMBL4037444 0.80 NR1H4 (0.48) NPC1RAB9ASMN1; SMN2CYP3A4CYP2C19
SCHEMBL4037604 0.79 MDM2 (0.48) SMN1; SMN2NR1H4ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed